🟢 Noveris Health Sciences is trading 13.04% up today on biotech momentum, with no clear catalyst

Noveris Health Sciences is trading higher on September 3, 2026, at CA$0.13, up 13.04%, as sector momentum supports the move despite no clear company-specific catalyst identified.

• Biotech sentiment is benefiting from Purple Biotech’s U.S. patent allowance for its CAPTN-3 cancer-immunotherapy platform.
• Major U.S. indexes and biotechnology shares are also advancing, supporting broader risk appetite.
• The move is best attributed to sector momentum rather than a Noveris announcement.